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Abstract Setting Fifteen community pharmacies in the
UK. Objective Proof of concept study to test the use of
community pharmacies for active case finding of patients
with coeliac disease. Methods Customers accessing over-
the counter and prescription medicines indicated in the
treatment of possible symptoms of coeliac disease over a
6 month period were offered a free point of care test. All
patients were given advice regarding the test results and
those who tested positive were advised to make an
appointment with their general practitioner. Patients and
pharmacists involved in service provision were asked to
complete a satisfaction survey. Pharmacists were addi-
tionally invited to undertake interviews to better under-
stand their views on the service. Main outcome measures
Feasibility of service, acceptability to stakeholders and
proportion testing positive for coeliac disease. Results Of
the 551 individuals tested, 52 (9.4 %) tested positive. 277
(50.3 %) were tested for accessing irritable bowel syn-
drome treatment, 142 (25.8 %) due to presenting for diar-
rhoea. The proportion of patients testing positive with
different symptoms or for different treatments were similar.
Of 43 customers who returned the satisfaction survey, all
would recommend the service to others, believing the
community pharmacy to be a suitable location. Community
pharmacists believed that it enabled them to improve
relationships with their customers and that medical prac-
tices were receptive to the service. Conclusion This proof
of concept study has shown that community pharmacies
using a point of care test can effectively recognise and refer
patients for confirmatory coeliac disease testing with high
levels of customer and service provider satisfaction.
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Kingdom
Impact of findings on practice
• Pharmacists and their staff should routinely explore
symptoms of diarrhoea to ensure that they are not long
term or recurrent as this may be indicative of undiag-
nosed coeliac disease.
• Patients who are receiving treatment for irritable bowel
syndrome, haven’t previously been tested for coeliac
disease and don’t experience symptom resolution
should be referred for possibility of coeliac disease.
• Community pharmacy is seen by both patients and
pharmacists as an appropriate location for the early
recognition of patients for whom further tests to
confirm diagnosis of coeliac disease are appropriate.
Introduction
Coeliac disease is an autoimmune condition triggered by
intolerance to gluten and characterised by inflammation of
the small intestine [1]. Whilst it is believed to affect 1 % of
the UK population [2, 3] only 24 % of those affected are
diagnosed [4]. Consequently there is an estimated half a
million people with coeliac disease in the UK who remain
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undiagnosed, reasons for which may include a lack of
awareness of the condition and misdiagnosis. One in four
people diagnosed with coeliac disease have previously
been treated for irritable bowel syndrome (IBS) [5]. The
symptoms of coeliac disease are similar to those of many
minor gastrointestinal problems which people may prefer
to discuss with their local pharmacist rather than having to
make an appointment to see their general practitioner (GP)
[6].
Delayed diagnosis and untreated coeliac disease is
associated with unexplained infertility, osteoporosis and in
rare cases, small bowel lymphoma [7]. The direct costs
associated with undiagnosed coeliac disease are increased
visits to the GP, use of medicines for symptomatic treat-
ment, increased investigations and referral [8, 9]. Whilst
screening and treating people with coeliac disease results in
significant improvements in quality of life [10, 11] sys-
tematic population screening is not recommended in the
UK [12] with current guidance recommends targeted
screening of those individuals with related symptoms or
associated conditions [7]. Individuals meeting the criteria
for screening should be offered serological tests for both
total immunoglobulin A (IgA) and IgA tissue transglu-
taminase antibodies (IgA tTGA). Total IgA levels are
required as approx. 2–3 % of patients with coeliac disease
will have an IgA deficiency [13, 14] and hence if IgA tTGA
is tested in isolation it can increase the number of false
negative results. Adults with a positive serological test
result should always be referred to secondary care for
endoscopy with biopsy to confirm or exclude coeliac dis-
ease [7].
Traditionally the identification and implementation of
targeted screening has solely been the role of primary care
physicians. They are however only able to identify patients
who present to them for treatment and advice. It is more
usual for patients with minor gastrointestinal symptoms to
self-treat with therapy which is available from pharmacies
and supermarkets [15]. To improve detection rates within
Hungary, district nurses were successfully used in primary
care to proactively screen for coeliac disease in young
children using a finger prick blood test [16] thus demon-
strating that other healthcare professionals located in pri-
mary care can effectively undertake screening for coeliac
disease.
Community pharmacies are increasingly being used to
deliver screening services due to their geographical spread,
extended opening hours, availability of trained healthcare
professionals and use by patients who may not normally
access medical services [17–19]. Furthermore with access
to patient medication records, community pharmacists can
identify patients treated for conditions which may be
indicative of coeliac disease. The recent availability of
reliable point of care tests (POCTs) [20] enables
community pharmacies to offer and undertake screening
for coeliac disease.
Aim of the study
The aim of this paper is to describe the proof of concept
study for a targeted case finding service for coeliac disease
using a small number of community pharmacies and
determine both its feasibility as a service and acceptability
to stakeholders.
Ethics approval
The study was deemed to be a service evaluation by the
University of East Anglia Faculty of Medicines and Health
Sciences Ethics Committee.
Methods
The case finding, proof of concept, service was provided
between April and October 2015.
Setting
Fifteen community pharmacies across England recruited
through the National Association of Primary Care’s Pri-
mary Innovation Network, and including Rowlands Phar-
macy and an Independent pharmacy agreed to participate.
Pharmacies were purposively recruited to ensure a wide
geographical spread, a mix of pharmacy locations i.e.
linked to GP practice or stand alone and from large mul-
tiple and independently managed companies. Participating
pharmacies were asked to contact local GP practices to
inform them of the study taking place.
Training and support
Participating pharmacists were expected to undertake an
online module on recognising and managing coeliac dis-
ease from the Centre for Pharmacy Postgraduate Educa-
tion, learning pharmacy website [21]. Posters for raising
awareness and information leaflets were supplied by Coe-
liac UK.
Senior pharmacists from the different companies were
involved in the service design and trained by Tillotts
Pharma Ltd on the use of the Simtomax POCTs. These
individuals then trained staff within the recruited pharma-
cies on the use of the POCTs, including how to identify,
approach and recruit patients and provide feedback after
testing. The majority of pharmacists also received in house
training, direct from Tillotts Pharma Ltd.
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Pharmacies received remuneration on commencement
of training, half way through and at the end of the study.
Service population
All customers who met the inclusion criteria outlined
below were given an information sheet which explained the
purpose of the service and process.
Inclusion criteria:
• Men and women aged 18 years and over receiving
prescribed treatments, or requesting OTC treatments for
either IBS and or iron, vitamin B12 or folate deficiency
anaemia.
• No previous diagnosis or investigation for coeliac
disease.
• Registered with a GP.
Those who subsequently expressed an interest were then
given a short questionnaire to complete to enable any of the
following exclusion criteria to be identified.
Exclusion criteria:
• Adults on a gluten-free diet or people excluding gluten
from their diets.
• Adults with learning disabilities.
• Adults who have a terminal illness.
• Adults unable to give verbal consent.
• Women receiving folate due to pregnancy.
• Adults previously tested for coeliac disease with a
negative result.
Symptoms and diagnoses of any associated conditions
were recorded using categories provided within the
bespoke pharmacy software which were based on NICE
guidance [7] and verbal consent obtained before testing
was undertaken.
Patients declining the test were asked to fill in a short
questionnaire to capture their reasons for declining, pro-
vided with an information leaflet on coeliac disease, and
signposted to their GP should any symptoms persist or re-
appear.
Intervention
The test, which measured both total immunoglobulin A
(IgA) and IgA tissue transglutaminase antibodies (IgA
tTGA), was provided for free to the patient and was under-
taken in a consultation room within the pharmacy by a
trained member of the pharmacy team. A finger prick blood
sample was taken and inserted into the testing device as per
standard operating procedure. In a pilot study the specificity
and sensitivity of the POCT used were found to be consistent
with current NHS laboratory tests for this disease [20].
Information provided in all patient leaflets highlighted
the possibility of false positive or negative test results and
outlined the need for further referral to confirm test results
in line with national guidance. Leaflets were designed to
ensure that participants were aware of the implications of
the test result and could make fully informed decisions as
to their future actions. On receipt of the result all partici-
pants were given a letter containing the results for their
records and the opportunity to ask further questions.
Customers with negative results were given a patient
leaflet, informed that the POCT indicated that they were
unlikely to have coeliac disease but if problems persist to
speak with their GP.
Customers with a positive result were provided with a
description of the POCT, confirmation of the result, an
information leaflet on coeliac disease, advised to see their
GP and not to change their diet as a result of this screening
test.
Sample size justification
A pragmatic approach was applied and each pharmacy was
requested to carry out 40 POCTs during the study period,
which after allowing for training and preparation for the
service in each pharmacy, equated to 2 POCTs per week.
Assuming that 600 POCTs were performed if the
detection rate was similar to that previously reported in an
at risk population of 9.6 % [22] then this would provide a
95 % CI of ±2.4 %.
Evaluation
For each participant their age, gender, medication which
triggered the approach for recruitment, present symptoms
and outcome of the test result were recorded.
All service recipients were asked to complete a short
satisfaction questionnaire which included a question on
whether they would have been prepared to pay for the
service and how much they would be willing to pay.
The pharmacy team also completed a baseline and end
of study questionnaire to determine their experience of
providing the service.
Interviews were undertaken with participating pharma-
cists, transcribed verbatim and anonymised by a repre-
sentative from Coeliac UK. Analysis consisted of a
framework approach [23]. After familiarisation with the
data a coding framework was developed and subsequently
applied to the transcripts. Constant reference was made to
the transcripts when abstracting themes and sub-themes
from the data to ensure meaning and context were retained.
Interpretation of the transcripts was checked by a second
researcher.
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Results
The minimum number of patients recruited in one phar-
macy was 9 with the maximum being 63 and 11 pharma-
cies out of 15 recruited to target.
551 people were tested for coeliac disease using the
POCT. Reasons for declining the test were provided by 15
individuals, 7 (46.7 %) stated lack of time as the primary
reason for declining the service with 3 (20 %) preferring to
discuss the issue with their GP. Participant demographics
are provided in Table 1.
Loperamide and mebeverine were the most common
medicines reported for triggering recruitment (summarised
in Table 2). 312 (56.6 %) patients were recruited due to
purchasing over the counter (OTC) medicines which are
potentially indicative of coeliac disease.
The symptoms patients reported to be experiencing prior
to consultation are provided in Table 3.
Of the 551 people tested, 9.4 % (52) were given a
positive result for coeliac disease. The reported symptoms
and indications for treatments related to those patients who
tested positive are provided in Table 4.
Customer satisfaction
Forty-three (7.9 %) customer experience questionnaires
were returned. 34 (79.1 %) were from females and 4
(9.3 %) had a positive result for coeliac disease. 41 patients
reported their age, 6 (14.6 %) were under the age of 30, 11
(26.8 %) from 31 to 50, 17 (41.5 %) from 51 to 70 and 7
(17.0 %) over the age of 70.
All 43 (100 %) respondents agreed that the pharmacy
provided a safe and confidential environment for the ser-
vice, the pharmacy team were able to answer all questions,
community pharmacy was the ideal place for this type of
service and would recommend the service to others.
One (2.3 %) respondent believed that service was of
some value, 21 (48.8 %) believed that it was valuable and
21 (48.8 %) very valuable.
Nine (20.9 %) patients were unwilling to pay for the
service, 29 (67.4 %) were willing to pay £10, 4 (9.3 %) £20
and 1 (2.3 %) £30.
A common theme was the professionalism of the service
and its informative nature.
‘‘The pharmacist was very professional’’ R4.
‘‘Very pleased to know one way or another’’ R23.
All 12 community pharmacists who completed the sur-
vey believed that community pharmacy was a suitable lo-
cation to carry out POCTs, they were confident in
performing the test, were willing to continue with the
service and recommend it to other pharmacists.
Eight participating pharmacists consented to be inter-
viewed. The analysis centred on providing the service,
patient feedback, interactions with GPs and future
recommendations.
Table 1 Summary of demographics of recruited participants
(n = 551)
Characteristic Group No. (%)
Gender Female 340 (61.7)
Age (years) 18–30 123 (24.9)
31–40 111 (20.1)
41–50 109 (19.8)
51–60 85 (15.4)
61–70 66 (12.0 %)
70? 42 (7.6)
Unknown 1 (0.2)
Table 2 Indications for
medicines which triggered
recruitment of participants
(n = 551)
Condition Trigger no. (%) Total no. (%)
Over the counter Prescription
Irritable bowel disease 152 (48.7) 125 (52.3) 277 (50.3)
Diarrhoea 122 (39.1) 20 (8.4) 142 (25.8)
Anaemia 16 (5.1) 58 (24.3) 74 (13.4)
Indigestion 17 (5.4) 17 (7.1) 34 (6.2)
Constipation 4 (1.3) 12 (5.0) 16 (2.9)
Other 1 (0.3) 7 (2.9) 8 (1.5)
Table 3 Symptoms reported by participants during pharmacist
consultation (n = 551)
Symptom experienced No. (%)a
Regular diarrhoea 199 (36.1)
General gastro-intestinal problems 241 (43.7)
Abdominal problems 286 (51.9)
Sudden or unexpected weight loss 19 (3.4)
Regular and severe mouth ulcers 19 (3.4)
Prolonged fatigue 146 (26.5)
Regular and unexplained anaemias 61 (11.1)
a Participants frequently reported more than one symptom and
therefore column does not add up to 100 %
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In terms of providing the service the pharmacists
highlighted that the relatively short training session was
easy to understand and effective at learning more about
the condition and testing methods. Pharmacists identified
that their staff could be heavily involved in identifying
and testing patients from training through to service
provision. One pharmacist stated that this proved useful
as someone else could perform the test and then they
could just look at the result and discuss this with the
patient.
Pharmacists also stated this service was useful at iden-
tifying not only patients who were ‘regulars’ within their
pharmacy but also those who came into buy OTC
medication.
‘‘…they were people that had come into buy some-
thing and we’ve offered them the test because of the
product they were buying, looked at their symp-
toms.’’ Ph3.
Once in the consultation, the pharmacists highlighted
that the service itself was relatively quick to perform and
could be used as a link to other pharmacy services such as
medicine use reviews (MURs).
‘‘…when I have a patient having a test I can offer
another service while they wait, so, ‘what about an
MUR?’’’ Ph6.
Pharmacists also identified that the service helped to
build rapport with patients.
‘‘It’s definitely I think built a better rapport with
them. Because I think you actually spending time
with them and doing these clinical things with them I
suppose builds a bit of trust with them…’’ Ph8.
Speed and accessibility of the service was a key
advantage. Pharmacists reported that patients would often
have to wait weeks or months for a test and sometimes may
not be offered one by their GP. An additional perceived
benefit of this quick turnaround, centred on patient
reassurance.
‘‘Well, they, to be honest a lot of them would say ‘ok,
at least it’s not that’’ Ph4.
Finally, after discussions with both GPs and patients,
pharmacists stated that GPs and medical practice staff were
receptive to the service being provided in community
pharmacy.
Conclusion
Point of care testing for coeliac disease in community
pharmacies was undertaken in this proof of concept study
from a range of settings with the majority of pharmacies
recruiting to or above expected target in the time allowed.
The majority of patients who were screened were in the
target age range with more than half identified because they
had presented to purchase OTC products. The medicine
groups which were the most likely to result in recruitment
were either for the treatment of IBS or diarrhoea. Most
recruits reported some form of gastrointestinal symptom
with almost a quarter reporting fatigue.
Whilst point of care testing of this nature is not sup-
ported by National Institute of Health and Care Excellence
(NICE) guidance, the test used mirrored NICE recom-
mendations with total immunoglobulin A (IgA) and IgA
tissue transglutaminase antibodies (IgA tTGA) both
determined. The detection rate was in line with similar
research which had focussed on those individuals at high
risk and consequently was relatively efficient. Patients
were very positive about the provision of such a service
from community pharmacies and community pharmacists
believed that this was an appropriate service to provide in
their setting. Whilst most patients reported that they would
be willing to pay for such a service, the actual cost, which
was greater than £20, would be prohibitive to most and
therefore alternative routes for funding would be required
if this was to be provided as a routine service.
The large number of patients recruited means that we
can estimate with 95 % confidence that the actual detection
Table 4 Proportion of patients
reporting different symptoms
who tested positive
Reported symptom No. (%)a Indication for therapy No. (%)a
Regular diarrhoea 26 (13.1) Irritable bowel syndrome 28 (10.1)
General gastro-intestinal problems 34 (14.1) Diarrhoea 10 (7.0)
Abdominal problems 31 (10.8) Anaemia 7 (5.9)
Sudden or unexpected weight loss 3 (15.8) Indigestion 2 (5.9)
Regular or severe mouth ulcers 1 (5.3) Constipation 4 (25.0)
Prolonged fatigue 18 (12.3)
Regular and unexplained anaemias 7 (11.5)
a Based on percentage of screened patients who reported that symptom during consultation (Table 3) or
indication for their therapy (Table 2)
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rate for such a service would be somewhere between 7 and
11.8 % which is relatively efficient when considering that
only 1 % of the total population have the condition and
would be found by population screening [3].
The response from the patient survey was limited with
respondents not truly reflecting the demographics of those
who had been recruited. Consequently their opinions may
not be representative of all participants. Response rate
could potentially be improved by asking participants to
complete the survey within the pharmacy rather than taking
it home, which was the method used here. Additionally
asking patients how much they would be willing to pay for
such a service may not reflect reality when the test can be
provided for free by their general practitioner.
Whilst half of the community pharmacists involved in
the study were interviewed there may be some self-selec-
tion bias with those less satisfied with the service being less
willing to express their views in a face to face interview.
Many of the patients testing positive for coeliac disease
were self-treating gastrointestinal symptoms and therefore
the community pharmacy is an ideal location to place such a
service. All patients receiving treatment for IBS will have
been diagnosed with the condition by their GP and again
these findings are in line with other studies regarding
potential misdiagnosis of this condition [5]. In 2015 the UK
NICE recommended that all patients are screened for coe-
liac disease prior to a confirmation of diagnosis of IBS [7]
and if widely adopted this would increase detection rates.
Patients who provided feedback were uniformly positive
about the setting, found the pharmacist able to answer their
questions and would recommend the service to others.
Individual patients commented on the professionalism
exhibited by the pharmacists and on the usefulness of the
information provided. Consequently this proof of concept
study strongly suggests that if such a service were to be
rolled out in a similar manner it would be acceptable to
patients. With community pharmacists ideally located to
monitor individuals once diagnosed with coeliac disease
and trained to provide dietary advice, screening could be
part of a more holistic service where the community phar-
macist works collaboratively with the primary care team.
Participating community pharmacists were also positive
regarding the experience, the training and the service
because it enabled them to develop better customer rela-
tions, consider their needs more holistically and identify
other services from which they may benefit. GPs were also
reported to be receptive to the service. This may have been
helped by the community pharmacies contacting them in
advance of service provision.
With patients in this study reportedly unwilling to pay
the actual cost of the service the question is whether the cost
of screening high risk individuals in this manner would be
offset by future reductions in health services cost. The
development of a model to estimate the cost-effectiveness
of this service from an NHS perspective is warranted.
The results of this service evaluation however can be
used to remind community pharmacists that patients pre-
senting for treatment of diarrhoea, IBS or non-specific
gastrointestinal symptoms may actually have coeliac dis-
ease and therefore require referral.
This proof of concept study has shown that community
pharmacies can be used to effectively screen for coeliac
disease and, the process is acceptable to both patients and
pharmacists. The cost-effectiveness of early detection of
people with coeliac disease using community pharmacies
however needs to be ascertained. Incorporating such
screening within a more holistic community pharmacy
based service including monitoring and advice may
enhance the quality of care currently provided and poten-
tially represent better value to commissioners.
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